During the past decade, Universitätsmedizin Essen conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Universitätsmedizin Essen" are "Cystic Fibrosis" (1 trials), "Healthy Subjects" (1 trials) and "NSCLC" (1 trials). Many other conditions were trialed in "Universitätsmedizin Essen" in a lesser frequency.

Most popular intervention types in "Universitätsmedizin Essen" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Brigatinib" (1 trials), "IONIS-ENaCRx" (1 trials), "Placebo" (1 trials) and "Tyrosine kinase inhibitor" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsmedizin Essen" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsmedizin Essen". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Universitätsmedizin Essen, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsmedizin Essen, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".